Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 11, 2007, Pages 1154-1160

  Skoro Sajer, Nika ^a   Mittermayer, Friedrich ^a   Panzenboeck, Adelheid ^a   Bonderman, Diana ^a   Sadushi, Roela ^a   Hitsch, Robert ^a   Jakowitsch, Johannes ^a   Klepetko, Walter ^a   Kneussl, Meinhard P ^b   Wolzt, Michael ^a   Lang, Irene M ^a,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chronic thromboembolic pulmonary hypertension; Nitric oxide; Nitric oxide synthase

Indexed keywords

N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTERY DISEASE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDARTERECTOMY; ENDOTHELIUM CELL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; THROMBOEMBOLISM;

AGED; ARGININE; CHRONIC DISEASE; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; OSMOLAR CONCENTRATION; PROGNOSIS; PULMONARY ARTERY; SEVERITY OF ILLNESS INDEX; THROMBOEMBOLISM;

EID: 36849078644     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200702-278OC     Document Type: Article

References (33)

1. Lang IM. Chronic thromboembolic pulmonary hypertension: not so rare after all. N Engl J Med 2004;350:2236-2238.
2. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-2264.
3. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001;345:1465-1472.
4. Moser KM, Metersky ML, Auger WR, Fedullo PF. Resolution of vascular steal after pulmonary thromboendarterectomy. Chest 1993;104:1441-1444.
5. Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, Large SR, Wells FC, Wallwork J. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991;324:1539-1547.
6. Cooper CJ, Landzberg MJ, Anderson TJ, Charbonneau F, Creager MA, Ganz P, Selwyn AP. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 1996;93:266-271.
7. Dweik RA. The lung in the balance: arginine, methylated arginines, and nitric oxide. Am J Physiol Lung Cell Mol Physiol 2006;292:L15-L17.
8. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001;37:489-492.
9. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper MM. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005;25:1414-1418.
10. Skoro-Sajer N, Mittermayer F, Bonderman D, Sadushi R., Hitsch R., Klepetko W, Kneussl M, Wolzt M, Lang IM. Asymmetrical dimethylarginine in chronic thromboembolic pulmonary hypertension (CTEPH) [abstract]. Am J Respir Crit Care Med 2007;175:A1000.
11. Skoro-Sajer N, Mittermayer F, Bonderman D, Wolzt M, Lang IM. L-arginine and asymmetrical dimethylarginine (ADMA) in chronic thromboembolic pulmonary hypertension (CTEPH) [abstract]. Proc Am Thorac Soc 2006;3:783.
12. Skoro-Sajer N, Bonderman D, Wiesbauer F, Harja E, Jakowitsch J, Klepetko W, Kneussl M, Lang I. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007;5:483-489.
13. Machherndl S, Kneussl M, Baumgartner H, Schneider B, Petkov V, Schenk P, Lang IM. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 2001;17:8-13.
14. Thistlethwaite PA, Mo M, Madani MM, Deutsch R, Blanchard D, Kapelanski DP, Jamieson SW. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg 2002;124:1203-1211.
15. Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W, Lang IM. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005;128:2599-2603.
16. Mittermayer F, Namiranian K, Pleiner J, Schaller G, Wolzt M. Acute Escherichia coli endotoxaemia decreases the plasma L-arginine/ asymmetrical dimethylarginine ratio in humans. Clin Sci (Lond) 2004;106:577-581.
17. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994;89:2715-2721.
18. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S-34S.
19. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-221.
20. Bulau P, Zakrzewicz D, Kitowska K, Leiper J, Gunther A, Grimminger F, Eickelberg O. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol 2006;292:L18-L24.
21. Arrigoni FI, Vallance P, Haworth SG, Leiper JM. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 2003;107:1195-1201.
22. Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, Carey RM, Johns RA. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 2003;108:1493-1498.
23. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W, Aigner C, Fink L, Muyal JP, Weissmann N, et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 2005;19:1175-1177.
24. Sasaki A, Doi S, Mizutani S, Azuma H. Roles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in rats. Am J Physiol Lung Cell Mol Physiol 2007;292:L1480-L1487.
25. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007;13:198-203.
26. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-177.
27. Haider DG, Bucek RA, Reiter M, Minar E, Hron G, Kyrle PA, Mittermayer F, Wolzt M. The cardiovascular risk marker asymmetrical dimethylarginine is not affected by venous thromboembolism. Transl Res 2006;148:26-29.
28. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation 2006;113:2011-2020.
29. Klepetko W, Mayer E, Sandoval J, Trulock EP, Vachiery JL, Dartevelle P, Pepke-Zaba J, Jamieson SW, Lang I, Corris P. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:73S-80S.
30. Kim NH. Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:584-588.
31. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-2575.
32. Ziegler S, Mittermayer F, Plank C, Minar E, Wolzt M, Schernthaner GH. Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease. J Clin Endocrinol Metab 2005;90:2175-2178.
33. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007;282:879-887.